ANG Lifesciences India Ltd.

62.90 +0.90 ▲1.5%

05 March 2024, 09:34:00 AM
Volume: 1

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.anglifesciences.com
Market Cap 80.96 Cr.
Enterprise Value(EV) 142.40 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) -8.50 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-12
Industry PE 41.59 Trailing Twelve Months Ending 2023-12
Book Value / Share 61.15 Trailing Twelve Months Ending 2023-12
Price to Book Value 1.01 Calculated using Price: 62.00
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 1.31 Cr. 13,058,287 Shares
FaceValue 10
About ANG Lifesciences India Ltd.
The company is ISO-9001:2008 certified and has the modern & sophisticated plant, equipments, technique and manpower. The planning and construction of plant has been done to conform to the regulatory requirements as per the norms of WHO G.M.P. and G.L.P. as per schedule-M (revised). They manufacture their products in compliance with GMP requirements. They have dedicated area, machinery, facilities and advanced equipments for manufacturing of B-Lactum & Non-B Lactum products as per GMP Norms. The production block provides appropriate personnel and material flow. As per GMP norms, all the production processes are documented and validated to establish the accuracy of the procedures and the control measures. The Company's production capacity is 700 Lakhs Pcs per annum on per shift basis. Their products include sterile dry powder vials for Anti Biotics, Anti Ulcerant, Gluco corticoid and Anti inflammatory, Anti malarial and Anesthetic.

ANG Lifesciences India Ltd. Delivery

Delivered Qty
Traded Qty

ANG Lifesciences India Ltd. Performance

1 Day
+1.45%
1 Week
-1.92%
1 Month
-8.46%
3 Month
-2.77%
6 Month
-16.61%
1 Year
-31.14%
2 Year
-72.34%
5 Year
+394.50%
10 Year

ANG Lifesciences India Ltd. Fundamental Ratios

2 years 2022-03 2023-03
Return on Equity (%) 48.13 -0.31
Return on Capital Employed (%) 39.14 9.53
Return on Assets (%) 14.06 -0.09

ANG Lifesciences India Ltd. Balance Sheet

Particulars 3 years 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 84 86 86
Non Curr. Liab. 37 27 23
Curr. Liab. 166 162 156
Minority Int.
Equity & Liab. 287 276 265
Non Curr. Assets 94 89 86
Curr. Assets 193 185 179
Misc. Exp. not W/O
Total Assets 287 276 265

ANG Lifesciences India Ltd. Profit and Loss

Particulars 3 years 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 354 220 148
Other Income 1 10 10
Total Income 355 230 157
Total Expenditure -286 -205 -152
PBIDT 69 24 6
Interest -9 -12 -9
Depreciation -6 -9 -9
Taxation -13 -3 1
Exceptional Items
PAT 40 0 -11
Minority Interest
Share Associate
Other Related Items 1
Consolidated Net Profit 40 0 -11
Adjusted EPS 31 0 -9

ANG Lifesciences India Ltd. Cash Flow

Particulars 2 years 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 25 26
Cash Fr. Inv. -44 -9
Cash Fr. Finan. 20 -17
Net Change 0 0
Cash & Cash Eqvt 0 0

ANG Lifesciences India Ltd. Shareholding Pattern

9 Qtrs 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%)
Promoter 71.07 71.09 71.14 71.15 71.15 71.15 70.60 70.60 70.60
Public 28.93 28.91 28.86 28.85 28.85 28.85 29.40 29.40 29.40
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 21.11 42.20 44.88 44.88 44.88 44.88 44.88 44.88 44.88

ANG Lifesciences India Ltd. Announcements

Fri, 16 Feb 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 & 47 please find enclosed herewith copies of Newspaper Advertisements of Unaudited Financial Results as on 31.12.2023.
Wed, 14 Feb 2024
Board Meeting Outcome for Outcome Of Board Meeting 14.02.2024.
Pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 we would like to inform you that Board of Directors in its meeting held on Wednesday 14th February 2024 has considered and approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the Quarter and Nine month ended on December 31 2023 along with the Limited Review Report thereon issued by M/s Singh Bhupinder & Associates Statutory Auditors of the Company.
Wed, 14 Feb 2024
Disclosure Of Unaudited Financial Results For Quarter And Nine Months Ended 31.12.2023.
Please find enclosed the Unaudited Financial Results for quarter and nine months ended 31.12.2023.

ANG Lifesciences India Ltd. Technical Scans

Mon, 04 Mar 2024
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
High Decrease in 1 Month High Decrease in 1 Month
High Decrease in 1 Year High Decrease in 1 Year
High Decrease in 2 Years High Decrease in 2 Years
High Increase in 5 Years High Increase in 5 Years

ANG Lifesciences India Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 372,436.77 1,549.00 -0.2%
Cipla Ltd. 118,783.64 1,473.80 +0.2%
Dr. Reddy's Laboratories Ltd. 105,691.98 6,325.50 -0.2%
Zydus Lifesciences Ltd. 95,764.63 943.50 -0.3%
Divi's Laboratories Ltd. 92,421.56 3,477.00 -0.2%
Torrent Pharmaceuticals Ltd. 91,038.44 2,692.05 +0.0%
Apollo Hospitals Enterprise Ltd. 86,787.70 6,056.15 +0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.82 1,549.00 -0.2%
Cipla Ltd. Consolidated 2023-12 32.03 1,473.80 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.22 6,325.50 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-12 32.20 943.50 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-12 66.83 3,477.00 -0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 60.94 2,692.05 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 109.95 6,056.15 +0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.97 1,549.00 -0.2%
Cipla Ltd. Consolidated 2023-12 4.59 1,473.80 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.93 6,325.50 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.93 943.50 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-12 7.09 3,477.00 -0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.73 2,692.05 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 12.85 6,056.15 +0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,549.00 -0.2%
Cipla Ltd. Consolidated 2023-03 0.02 1,473.80 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,325.50 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 943.50 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,477.00 -0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,692.05 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,056.15 +0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,549.00 -0.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,473.80 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,325.50 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 943.50 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,477.00 -0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,692.05 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,056.15 +0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,549.00 -0.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,473.80 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,325.50 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 943.50 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,477.00 -0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,692.05 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,056.15 +0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,549.00 -0.2%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,473.80 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,325.50 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 943.50 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,477.00 -0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,692.05 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,056.15 +0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,549.00 -0.2%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,473.80 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,325.50 -0.2%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 943.50 -0.3%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,477.00 -0.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,692.05 +0.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,056.15 +0.4%

ANG Lifesciences India Ltd. FAQ's

What is ANG Lifesciences share price?

Can I buy ANG Lifesciences shares now?

What is the Market Cap of ANG Lifesciences?

What are the key metrics to analyse ANG Lifesciences?

What is the 52 Week High and Low of ANG Lifesciences?

What is the trend of ANG Lifesciences share price?